Euglycemic Ketoacidosis: Diagnosis and Management
Euglycemic diabetic ketoacidosis (euDKA) is diagnosed when blood glucose is <250 mg/dL in the presence of metabolic acidosis (pH <7.3, bicarbonate <15-18 mEq/L) and ketonemia, and should be managed with simultaneous administration of intravenous insulin AND dextrose-containing fluids from the outset 1, 2.
Diagnostic Criteria
The key diagnostic triad for euDKA includes:
- Blood glucose <250 mg/dL (often <200 mg/dL, sometimes even normal)
- Metabolic acidosis: venous pH <7.3, bicarbonate <15-18 mEq/L, elevated anion gap
- Ketonemia: β-hydroxybutyrate >3 mmol/L (preferred) or positive serum/urine ketones 1, 3
Critical diagnostic pitfall: The normal or near-normal glucose leads to missed or delayed diagnosis because clinicians don't consider DKA without marked hyperglycemia 1, 3. Always measure ketones (preferably β-hydroxybutyrate) in any diabetic patient with unexplained metabolic acidosis, regardless of glucose level 4, 3.
High-Risk Clinical Scenarios
Suspect euDKA in these specific contexts:
- SGLT2 inhibitor use (most common modern cause) 1, 2, 5, 6
- Starvation states or prolonged fasting
- Pregnancy with diabetes
- Chronic liver disease
- Heavy alcohol use
- Acute illness with poor oral intake 1, 5, 6
Important: EuDKA can occur within 48-72 hours of SGLT2 inhibitor initiation, especially in treatment-naive patients experiencing common side effects like metformin-induced nausea 5, 6. This is much earlier than the typical ≥2 week timeframe previously described.
Laboratory Assessment
Obtain these specific tests:
- Venous blood gas (adequate for pH and bicarbonate; arterial not necessary) 4
- β-hydroxybutyrate (preferred over nitroprusside-based ketone tests) 4
- Comprehensive metabolic panel with anion gap calculation
- Blood glucose
- Serum osmolality
Critical monitoring caveat: Nitroprusside-based ketone tests (urine dipstick, serum acetoacetate) are misleading during treatment because β-hydroxybutyrate converts to acetoacetate, making ketosis appear to worsen when it's actually improving 4. Use β-hydroxybutyrate for monitoring response to therapy.
Management Protocol
Immediate Initial Steps (First Hour)
The fundamental difference from classic DKA management is that euDKA requires glucose administration from the start 2:
Start IV fluids with dextrose immediately: Use dextrose-containing solution (D5 or D10 in normal saline) at 1.5-2 times maintenance (approximately 150-250 mL/hour for adults) 2
Begin continuous insulin infusion: 0.1 units/kg/hour regular insulin IV 4, 7
Potassium replacement: Start when K+ <5.3 mEq/L (use 2/3 KCl and 1/3 KPO4) 4
- Critical warning: Hypokalaemia occurs in ~50% during treatment and severe hypokalaemia (<2.5 mEq/L) increases mortality 7
Why This Approach Differs
The immediate glucose administration in euDKA serves two purposes:
- Prevents hypoglycemia from insulin therapy
- Induces endogenous insulin secretion, which helps stop ketogenesis 2
This is opposite to classic DKA where you wait until glucose reaches 250 mg/dL before adding dextrose 4.
Monitoring During Treatment
Check every 2-4 hours:
- Venous pH and bicarbonate
- Serum electrolytes (especially potassium)
- Blood glucose
- β-hydroxybutyrate 4
- Anion gap
Adjust insulin rate: If glucose doesn't fall by 50 mg/dL in the first hour, verify hydration status and double insulin infusion hourly until achieving 50-75 mg/dL/hour decline 4.
Maintain glucose 150-200 mg/dL during treatment by adjusting dextrose concentration in IV fluids while continuing insulin to clear ketones 4.
Resolution Criteria
EuDKA is resolved when ALL of the following are met:
- Glucose <200 mg/dL
- Serum bicarbonate ≥18 mEq/L
- Venous pH >7.3
- Anion gap normalized 4
Important timing consideration: Ketonemia takes longer to clear than hyperglycemia, so continue insulin until ketones normalize even if glucose is controlled 4. With SGLT2 inhibitors, euDKA may be more prolonged due to the drug's half-life 2.
Transition to Subcutaneous Insulin
Once resolved and patient can eat:
- Calculate total daily dose from last 12 hours of IV insulin (e.g., 1.5 units/hour × 24 = 36 units/day)
- Give first subcutaneous dose (basal + prandial insulin)
- Continue IV insulin for 1-2 hours after subcutaneous dose to prevent rebound hyperglycemia and ketosis 4
Special Consideration for SGLT2 Inhibitors
Permanently discontinue SGLT2 inhibitors in patients who develop euDKA 5, 6. The risk of recurrence is too high to justify continuation, even though these agents have cardiovascular and renal benefits.
Common Pitfalls to Avoid
- Missing the diagnosis because glucose isn't elevated—always check ketones in diabetic patients with acidosis
- Using nitroprusside-based ketone tests for monitoring—they falsely suggest worsening
- Starting insulin without glucose in euDKA—causes dangerous hypoglycemia
- Stopping IV insulin abruptly when transitioning to subcutaneous—causes rebound ketosis
- Inadequate potassium monitoring—hypokalaemia is common and deadly
- Restarting SGLT2 inhibitors after euDKA—contraindicated due to recurrence risk